Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK

What: Corcept Therapeutics (CORT) stock surged **19.7%** after the FDA approved Lifyorli.
Why: The approval is a significant milestone for the company, marking a major breakthrough in its pipeline.
Signal: The FDA's green light sends a strong signal to investors that Lifyorli has met the necessary safety and efficacy standards.
Target: The company is likely to set its sights on commercializing Lifyorli, with potential for significant revenue growth.
Risk: However, the company may face increased competition and regulatory scrutiny in the coming months.